Xin Lang Cai Jing·2025-10-29 06:29Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Junshi Biosciences, indicating a slight decline in stock price and significant trading volume on October 28 [1] - On October 28, Junshi Biosciences experienced a financing buy-in amount of 23.10 million yuan, with a net financing buy of 0.79 million yuan, while the total financing and securities lending balance reached 1.39 billion yuan [1] - The financing balance of Junshi Biosciences is at a high level, accounting for 4.65% of the circulating market value, exceeding the 90th percentile of the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported an operating income of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year growth of 35.72% [2] - As of September 30, 2025, the number of shareholders of Junshi Biosciences increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% [2]